AGIO

Agios Pharmaceuticals Stock Price

50.19
-0.96 (-1.88%)
50.19

Low
32.47

52 Week Range

High
62.155

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Agios Pharmaceuticals Inc AGIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.96 -1.88% 50.19 18:00:19
Open Price Low Price High Price Close Price Prev Close
51.43 49.03 51.86 50.19 51.15
Bid Price Ask Price Spread News
49.75 61.00 11.25 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16,877 1,906,357 $ 50.01 $ 95,335,209 - 32.47 - 62.155
Last Trade Time Type Quantity Stock Price Currency
16:43:26 priorref 11,894 $ 50.19 USD

Period:

Draw Mode:

Agios Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.09B 61.57M 38.34M $ 203.20M $ - -4.74 2.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -46.19k 1.30%

more financials information »

Agios Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AGIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week56.6057.2249.0353.12959,780-6.41-11.33%
1 Month56.5558.6149.0355.641,060,500-6.36-11.25%
3 Months55.6462.15549.0356.26725,666-5.45-9.8%
6 Months47.8662.15544.3253.71730,7572.334.87%
1 Year52.6462.15532.4746.86736,725-2.45-4.65%
3 Years91.8893.9827.77448.37648,456-41.69-45.37%
5 Years42.2399.824227.77452.04604,6237.9618.85%

Agios Pharmaceuticals Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.


Your Recent History
NASDAQ
AGIO
Agios Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.